Jelle Wesseling
Professor by special appointment Pathology, in particular breast pathology
- Name
- Prof.dr. J. Wesseling
- Telephone
- +31 71 526 6622
- j.wesseling@nki.nl
- ORCID iD
- 0000-0002-8940-2676
Professor of pathology, in particular breast pathology, by special appointment. Affiliation: Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, on behalf of the LUMC. Recent awards 2017: Cancer Research UK Grand Challenge Award (in partnership with the Dutch Cancer Society). 2018: Value-based Health Care Dragon Grant Award for the LORD trial. 2020: Nominated for the AACR Scientific Achievement Award.
Breast pathology
Regarding the experience and skills of Prof. Jelle Wesseling in clinical, diagnostic breast pathology, he is internationally acknowledged as consultant breast pathologist as well as supervisor of residents in pathology. He is co-authoring a number of books on breast pathology, including the latest edition of the WHO-book on classification of tumors.
Regarding educational and mentoring activities, Jelle Wesseling is a highly rated lecturer and invited speaker at a multitude of meetings, institutes, and universities for a variety of audiences, such as students, patient organizations, oncologists, surgeons, epidemiologists, and pathologists. He has much appreciated mentoring skills in guiding PhD students, both in his own team as well as across the institute. He also brings the message of his research across to the Dutch society frequently, as illustrated by multiple appearances in national newspapers, magazines, radio broadcasts, and Dutch television news shows.
Academic career
Professor Jelle Wesseling achieved his MD in Medicine and MSc in Chemistry, both cum laude, at the University of Groningen and at the Free University of Amsterdam. He received his PhD at the Netherlands Cancer Institute in 1997, studying the role of MUC1 (EMA) in cell adhesion, signaling and invasion in cancer, supervised by Prof. Piet Borst, Prof. Carl Figdor and Dr. John Hilkens. In 2004, he was registered as pathologist after five years of training at the University Medical Center in Groningen. He held his inaugural lecture ‘Breast cancer: less is more’ at the Leiden University on May 24, 2019. He is consultant breast pathologist at the Netherlands Cancer Institute – Antoni van Leeuwenhoek and Leiden University Medical Center. His training both as basic scientist and as practicing clinical pathologist provides the ideal skillset for combining these two worlds to achieve a comprehensive transition from bench-to-bedside.
His overarching research focus is to develop new strategies to substantially improve the prognostic and predictive power of breast cancer pathology and to understand the underlying biology. Ultimately, he aims to define with high accuracy who to treat, how to treat and, if so, for what benefit and so achieve the best benefit-to-harm ratio for women with DCIS and IBC. A major highlight of his career was receiving the Cancer Research UK Grand Challenge Award ‘When cancer is not really cancer’ in 2017. In partnership with KWF Dutch Cancer Society, this award comes with 15-million-Euro funding and was based on his previous DCIS research and his initiative to build a strong, multidisciplinary, global team of experts to PREvent ductal Carcinoma In SItu Overtreatment Now (PRECISION).
Professor by special appointment Pathology, in particular breast pathology
- Faculteit Geneeskunde
- Divisie 4
- Pathologie
Contact
- Bornes, L.; Winden, L.J. van; Geurts, V.C.M.; Bruijn, B. de; Azarang, L.; Lanfermeijer, M.; Caruso, M.; Proost, N.; Boeije, M.; Lohuis, J.O.; Belthier, G.; Delgado, E.N.; Gruil, N. de; Kroep, J.R.; Ven, M. van de; Menezes, R.; Wesseling, J.; Kok, M.; Linn, S.; Broeks, A.; Rossum, H.H. van; Scheele, C.L.G.J. & Rheenen, J. van (2025), The oestrous cycle stage affects mammary tumour sensitivity to chemotherapy, Nature 637.
- Hutten, S.J.; Messal, H.A.; Lips, E.H.; Sheinman, M.; Ciwinska, M.; Braams, E.; Borden, C. van der; Kristel, P.; Stoffers, S.; Wessels, L.F.A.; Jonkers, J.; Rheenen, J. van; Wesseling, J.; Scheele, C.L.G.J. & Grand Challenge PRECISION Consorti (2024), Ductal carcinoma in situ develops within clonal fields of mutant cells in morphologically normal ducts, The Journal of Pathology 263(3): 360-371.
- Byng, D.; Schaapveld, M.; Lips, E.H.; Duijnhoven, F.H. van; Wesseling, J.; Harten, W.H. van & Retèl, V.P. (2024), An early economic evaluation of active surveillance for low-risk ductal carcinoma in situ, Future Oncology 20(40): 3451-3462.
- Alaeikhanehshir, S.; Voets, M.M.; Duijnhoven, F.H. van; Lips, E.H.; Groen, E.J.; Oirsouw, M.C.J. van; Hwang, S.E.; , J.Y. lo; Wesseling, J.; Mann, R.M.; Teuwen, J. & Grand Challenge PRECISION (2024), Application of deep learning on mammographies to discriminate between low and high-risk DCIS for patient participation in active surveillance trials, Cancer Imaging 24(1).
- Engelhardt, E.G.; Schmitz, R.S.J.M.; Gerritsma, M.A.; Sondermeijer, C.M.T.; Verschuur, E.; Houtzager, J.H.E.; Griffioen, R.; Bijker, N.; Mann, R.M.; Retèl, V.; Duijnhoven, F.H. van; Wesseling, J.; Bleiker, E.M.A. & Grand Challenge PRECISION Consortium (2024), DCIS knowledge of women choosing between active surveillance and surgery for low-risk DCIS, The Breast 77.
- Delaloge, S.; Khan, S.A.; Wesseling, J. & Whelan, T. (2024), Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment, The Lancet 403(10445): 2734-2746.
- Ommen-Nijhof, A. van; Steenbruggen, T.G.; Wiersma, T.G.; Balduzzi, S.; Daletzakis, A.; Holtkamp, M.J.; Delfos, M.; Schot, M.; Beelen, K.; Siemerink, E.J.M.; Heijns, J.; Mandjes, I.A.; Wesseling, J.; Rosenberg, E.H.; Peeters, M.J.T.V.; Linn, S.C. & Sonke, G.S. (2024), Intensified alkylating chemotherapy for patients with oligometastatic breast cancer harboring homologous recombination deficiency, European Journal of Cancer 213.
- Schmidt, M.K.; Lips, E.H.; Schmitz, R.S.J.M.; Verschuur, E. & Wesseling, J. (2024), Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ, BMJ-BRITISH MEDICAL JOURNAL 384.
- O'Leary, R.L.; Duijm, L.E.M.; Boersma, L.J.; Sangen, M.J.C. van der; Munck, L. de; Wesseling, J.; Schipper, R.J. & Voogd, A.C. (2024), Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands, British Journal of Cancer 131.
- Opdam, M.; Rossum, A.G.J. van; Hoogstraat, M.; Bounova, G.; Horlings, H.M.; Werkhoven, E. van; Mandjes, I.A.M.; Leeuwen-Stok, A.E. van; Canisius, S.; Tinteren, H. van; Imholz, A.L.T.; Portielje, J.E.A.; Bos, M.E.M.M.; Bakker, S.; Wesseling, J.; Kester, L.; Rheenen, J. van; Rutgers, E.J.; Menezes, R.X. de; Wessels, L.F.A.; Kok, M.; Oosterkamp, H.M.; Linn, S.C. & MATADOR trialists' grp Dutch Breast Canc Res Grp BOOG (2024), Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial, iScience 27(8).
- Boo, L.W.D.; Józwiak, K.; Hoeve, N.D.T.; Diest, P.J. van; Opdam, M.; Wang, Y.; Schmidt, M.K.; Jong, V. de; Kleiterp, S.; Cornelissen, S.; Baars, D.; Koornstra, R.H.T.; Kerver, E.D.; Dalen, T. van; Bins, A.D.; Beeker, A.; Heiligenberg, S.M. van den; Jong, P.C.D.; Bakker, S.D.; Rietbroek, R.C.; Konings, I.R.; Blankenburgh, R.; Bijlsma, R.M.; Imholz, A.L.T.; Stathonikos, N.; Vreuls, W.; Sanders, J.; Rosenberg, E.H.; Koop, E.A.; Varga, Z.; Deurzen, C.H.M. van; Mooyaart, A.L.; Córdoba, A.; Groen, E.; Bart, J.; Willems, S.M.; Zolota, V.; Wesseling, J.; Sapino, A.; Chmielik, E.; Ryska, A.; Broeks, A.; Voogd, A.C.; Wall, E. van der; Siesling, S.; Salgado, R.; Dackus, G.M.H.E.; Hauptmann, M.; Kok, M. & Linn, S.C. (2024), Prognostic value of histopathologic traits independent of stromal tumor-infiltrating lymphocyte levels in chemotherapy-naïve patients with triple-negative breast cancer, ESMO Open 9(3).
- Bockstal, M.R. van; Wesseling, J.; Lips, E.H.; Smidt, M.; Galant, C. & Deurzen, C.H.M. van (2024), Systematic assessment of HER2 status in ductal carcinoma in situ of the breast, Breast Cancer Research 26(1).
- Almekinders, M.M.; Bismeijer, T.; Kumar, T.; Yang, F.; Thijssen, B.; Linden, R. van der; Rooijen, C. van; Vonk, S.; Sun, B.H.; Cuentas, E.R.P.; Wistuba, I.I.; Krishnamurthy, S.; Visser, L.L.; Seignette, I.M.; Hofland, I.; Sanders, J.; Broeks, A.; Love, J.K.; Menegaz, B.; Wessels, L.; Thompson, A.M.; Visser, K.E. de; Hooijberg, E.; Lips, E.; Futreal, A.; Wesseling, J. & Grand Challenge PRECISION Consor (2022), Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk, British Journal of Cancer 127(7): 1201-1213.
- Eijkelboom, A.H.; Munck, L. de; Peeters, M.J.T.F.D.V.; Broeders, M.J.M.; Strobbe, L.J.A.; Bos, M.E.M.M.; Schmidt, M.K.; Paez, C.G.; Smidt, M.L.; Bessems, M.; Verloop, J.; Linn, S.; Lobbes, M.B.I.; Honkoop, A.H.; Bongard, D.H.J.G. van den; Westenend, P.J.; Wesseling, J.; Oordt, C.W.M. van; Tjan-Heijnen, V.C.G.; Siesling, S.; NABON COVID 19 Consortium & COVID Canc-NL Consortium (2021), Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study, Journal of Hematology and Oncology 14(1).
- Almekinders, M.M.M.; Schaapveld, M.; Thijssen, B.; Visser, L.L.; Bismeijer, T.; Sanders, J.; Isnaldi, E.; Hofland, I.; Mertz, M.; Wessels, L.F.A.; Broeks, A.; Hooijberg, E.; Zwart, W.; Lips, E.H.; Desmedt, C.; Wesseling, J. & Grand Challenge PRECISION Consort (2021), Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ, npj Breast Cancer 7(1).
- Seijen, M. van; Lips, E.H.; Fu, L.P.; Giardiello, D.; Duijnhoven, F. van; Munck, L. de; Elshof, L.E.; Thompson, A.; Sawyer, E.; Ryser, M.D.; Hwang, E.S.; Schmidt, M.K.; Elkhuizen, P.H.M.; Wesseling, J.; Schaapveld, M. & Grand Challenge Precision Consorti (2021), Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast, British Journal of Cancer 125(10): 1443-1449.